Synnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K.
-
Sophia Genetics SA (SOPH) PT Raised to $8 at BTIG
-
BTIG Reiterates Buy Rating on Sophia Genetics SA (SOPH)
-
SOPHiA GENETICS SA (SOPH) Misses Q4 EPS by 6c ; Offers Guidance
-
SOPHiA GENETICS signs two major US health systems for genomic testing
-
SOPHiA GENETICS promotes Ross Muken to CEO, reports Q4 revenue growth
-
SOPHiA GENETICS partners with Complete Genomics for oncology testing
-
SOPHiA GENETICS partners with Element Biosciences for sequencing analytics
-
Sophia Genetics SA (SOPH) PT Raised to $7 at BTIG
-
SOPHiA GENETICS SA (SOPH) Misses Q3 EPS by 7c ; Offers Guidance
-
A.D.A.M. Innovations partners with SOPHiA GENETICS for Japan testing
-
SOPHiA GENETICS launches AI digital twin technology for cancer treatment
-
Myriad Genetics partners with SOPHiA GENETICS on liquid biopsy test
-
SOPHiA GENETICS expands AstraZeneca partnership for cancer detection
-
SOPHiA GENETICS partners with Belgium hospital for genomic testing
-
Sophia Genetics SA (SOPH) PT Raised to $6 at BTIG
-
SOPHiA GENETICS SA (SOPH) Misses Q2 EPS by 11c, provides guidance
-
SOPHiA GENETICS expands AstraZeneca partnership for AI breast cancer research
-
SOPHiA GENETICS SA (SOPH) Misses Q1 EPS by 4c ; Offers Guidance
-
SOPHiA GENETICS (SOPH) Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR
-
Sophia Genetics SA (SOPH) PT Lowered to $5 at BTIG
-
SOPHiA GENETICS SA (SOPH) Misses Q4 EPS by 2c, provides guidance
-
SOPHiA GENETICS (SOPH) Launches Comprehensive MRD Tracking Capabilities
-
SOPHiA GENETICS SA (SOPH) Misses Q3 EPS by 6c ; Offers Guidance
-
SOPHiA GENETICS (SOPH) Appoints George Cardoza as CFO, Ross Muken as President
-
TD Cowen Reiterates Buy Rating on Sophia Genetics SA (SOPH)
-
SOPHiA GENETICS (SOPH) and AstraZeneca (AZN) Partner to Further Expand Global Access to Liquid Biopsy Testing
-
SOPHiA GENETICS (SOPH) Announces Validation of Novel Clinical Trial Assay Together with Precision for Medicine at World Clinical Biomarkers & CDx 2024
-
SOPHiA GENETICS (SOPH) DDM Platform Certified Under IVDR
-
Morgan Stanley Downgrades Sophia Genetics SA (SOPH) to Equalweight, 'Macro Weighs On Qtr/Guide'
-
SOPHiA GENETICS SA (SOPH) Tops Q2 EPS by 3c, Misses on Revenue; Offers FY24 Revenue Guidance
-
SOPHiA GENETICS (SOPH) Announces Expanded Relationship with OncoHelix
-
Guggenheim Starts Sophia Genetics SA (SOPH) at Buy

